Join Growin Stock Community!

Galecto, inc.GLTO.US Overview

US StockHealthcare
(No presentation for GLTO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

GLTO AI Insights

GLTO Overall Performance

GLTO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

GLTO Recent Performance

-5.27%

Galecto, inc.

0.05%

Avg of Sector

-0.31%

S&P500

GLTO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

GLTO Key Information

GLTO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

GLTO Profile

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

Price of GLTO

GLTO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

GLTO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-9.92
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
267.31
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-9.92
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
267.31
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is GLTO's latest earnings report released?

    The most recent financial report for Galecto, inc. (GLTO) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GLTO's short-term business performance and financial health. For the latest updates on GLTO's earnings releases, visit this page regularly.

  • How much cash does GLTO have?

    At the end of the period, Galecto, inc. (GLTO) held Total Cash and Cash Equivalents of 7.61M, accounting for 0.71 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is GLTO's EPS continuing to grow?

    According to the past four quarterly reports, Galecto, inc. (GLTO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -2.36. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of GLTO?

    Galecto, inc. (GLTO)'s Free Cash Flow (FCF) for the period is -2.62M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 28.35% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of GLTO?

    The latest valuation data shows Galecto, inc. (GLTO) has a Price-To-Earnings (PE) ratio of -0.49 and a Price/Earnings-To-Growth (PEG) ratio of 0.04. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.